open access

Vol 5, No 4 (2020)
Research paper
Published online: 2020-10-28
Get Citation

Place of magnesium sulfate in cardiopulmonary resuscitation. A systematic review and meta-analysis

Kobi Ludwin1, Jacek Smereka12, Milosz J. Jaguszewski3, Krzysztof J. Filipiak4, Jerzy R. Ladny15, Lukasz Szarpak617, Sylwia Wozniak8, Togay Evrin9
·
Disaster Emerg Med J 2020;5(4):182-189.
Affiliations
  1. Polish Society of Disaster Medicine, Warsaw, Poland
  2. Department of Emergency Medical Service, Wroclaw Medical University, Wroclaw, Poland
  3. First Department of Cardiology, Medical University of Gdansk, Poland
  4. First Chair and Department of Cardiology, Medical University of Warsaw, Poland
  5. Department of Emergency Medicine, Medical University of Bialystok, Poland
  6. Bialystok Oncology Center, Bialystok, Poland
  7. Maria Skłodowska-Curie Medical Academy in Warsaw, Poland
  8. Students Research Club, Maria Sklodowska-Curie Medical Academy in Warsaw, Poland
  9. Department of Emergency Medicine, Ufuk University Medical Faculty, Dr Ridvan Ege Education and Research Hospital, Ankara, Türkiye

open access

Vol 5, No 4 (2020)
ORIGINAL ARTICLES
Published online: 2020-10-28

Abstract

INTRODUCTION: Sudden cardiac arrest treatment is challenging, And the effectiveness of resuscitation procedures — especially in pre-hospital conditions — is low. The purpose of this meta-analysis is to investigate the effects of magnesium sulfate (MgSO4) in cardiac arrest on the return of spontaneous circulation (ROSC) and survival to hospital discharge.   MATERIAL AND METHODS: We searched in MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov, Web of Science up to May 25, 2020, and we conducted a systematic review and meta-analysis. We synthesized results by using mean differences, and odds ratios. The overall incidence and outcome of cardiac arrest were assessed using a random-effects meta-analysis.   RESULTS: A total of 5 eligible studies were included in this meta-analysis. Survival to discharge was higher in magnesium sulfate group compared to placebo group (9,5% vs. 8.2% respectively; OR = 1.17; 95% CI: 0.61, 2.23; p = 0.64). Higher survival rate to hospital admission was observed in the placebo group — 26.9% compared to the group where magnesium was administered — 25.7% (OR = 0.93; 95% CI: 0.59, 1.47; p = 0.77.   CONCLUSIONS: In conclusion, this meta-analysis indicates no statistically significant benefit of resuscitation with magnesium sulfate compared to the placebo. Thus, due to the low number of studies we recommend future randomized controlled trials to identify which anti-arrhythmic drug we should use on shock-refractory cardiac arrest.

Abstract

INTRODUCTION: Sudden cardiac arrest treatment is challenging, And the effectiveness of resuscitation procedures — especially in pre-hospital conditions — is low. The purpose of this meta-analysis is to investigate the effects of magnesium sulfate (MgSO4) in cardiac arrest on the return of spontaneous circulation (ROSC) and survival to hospital discharge.   MATERIAL AND METHODS: We searched in MEDLINE, EMBASE, Scopus, and ClinicalTrials.gov, Web of Science up to May 25, 2020, and we conducted a systematic review and meta-analysis. We synthesized results by using mean differences, and odds ratios. The overall incidence and outcome of cardiac arrest were assessed using a random-effects meta-analysis.   RESULTS: A total of 5 eligible studies were included in this meta-analysis. Survival to discharge was higher in magnesium sulfate group compared to placebo group (9,5% vs. 8.2% respectively; OR = 1.17; 95% CI: 0.61, 2.23; p = 0.64). Higher survival rate to hospital admission was observed in the placebo group — 26.9% compared to the group where magnesium was administered — 25.7% (OR = 0.93; 95% CI: 0.59, 1.47; p = 0.77.   CONCLUSIONS: In conclusion, this meta-analysis indicates no statistically significant benefit of resuscitation with magnesium sulfate compared to the placebo. Thus, due to the low number of studies we recommend future randomized controlled trials to identify which anti-arrhythmic drug we should use on shock-refractory cardiac arrest.

Get Citation

Keywords

magnesium sulfate, antiarrhythmic agents, cardiopulmonary resuscitation, advanced cardiovascular life support, meta-analysis, a systematic review

Supp./Additional Files (1)
Supplementary digital file
Download
163KB
About this article
Title

Place of magnesium sulfate in cardiopulmonary resuscitation. A systematic review and meta-analysis

Journal

Disaster and Emergency Medicine Journal

Issue

Vol 5, No 4 (2020)

Article type

Research paper

Pages

182-189

Published online

2020-10-28

Page views

1084

Article views/downloads

1090

DOI

10.5603/DEMJ.a2020.0041

Bibliographic record

Disaster Emerg Med J 2020;5(4):182-189.

Keywords

magnesium sulfate
antiarrhythmic agents
cardiopulmonary resuscitation
advanced cardiovascular life support
meta-analysis
a systematic review

Authors

Kobi Ludwin
Jacek Smereka
Milosz J. Jaguszewski
Krzysztof J. Filipiak
Jerzy R. Ladny
Lukasz Szarpak
Sylwia Wozniak
Togay Evrin

References (25)
  1. Deheinzelin D, Negri EM, Tucci MR, et al. Hypomagnesemia in critically ill cancer patients: a prospective study of predictive factors. Braz J Med Biol Res. 2000; 33(12): 1443–1448.
  2. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339: b2700.
  3. Savović J, Weeks L, Sterne JAC, et al. Cochrane Bias Methods Group, Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343(1): d5928–85.
  4. Szarpak L, Filipiak KJ, Mosteller L, et al. Survival, neurological and safety outcomes after out of hospital cardiac arrests treated by using prehospital therapeutic hypothermia: A systematic review and meta-analysis. Am J Emerg Med. 2020 [Epub ahead of print].
  5. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5: 13.
  6. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11): 1539–1558.
  7. Allegra J, Lavery R, Cody R, et al. Magnesium sulfate in the treatment of refractory ventricular fibrillation in the prehospital setting. Resuscitation. 2001; 49(3): 245–249.
  8. Fatovich DM, Prentice DA, Dobb GJ. Magnesium in cardiac arrest (the magic trial). Resuscitation. 1997; 35(3): 237–241.
  9. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J. 2002; 19(1): 57–62.
  10. Miller B, Craddock L, Hoffenberg S, et al. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation. 1995; 30(1): 3–14.
  11. Thel MC, Armstrong AL, McNulty SE, et al. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet. 1997; 350(9087): 1272–1276.
  12. Thomas SHL, Behr ER. Pharmacological treatment of acquired QT prolongation and torsades de pointes. Br J Clin Pharmacol. 2016; 81(3): 420–427.
  13. Lazzerini PE, Bertolozzi I, Finizola F, et al. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Front Pharmacol. 2018; 9: 363.
  14. Geiger H, Wanner C. Magnesium in disease. Clin Kidney J. 2012; 5(Suppl 1): i25–i38.
  15. Normansell R, Knightly R, Milan SJ, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2017; 11: CD003898–33.
  16. Griffiths B, Kew KM, Normansell R, et al. Intravenous magnesium sulfate for treating children with acute asthma in the emergency department. Cochrane Database Syst Rev. 2016; 4: CD011050–47.
  17. Bilotta F, Gelb AW, Stazi E, et al. Pharmacological perioperative brain neuroprotection: a qualitative review of randomized clinical trials. Br J Anaesth. 2013; 110 Suppl 1: i113–i120.
  18. Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007(3): CD000277.
  19. Dorhout Mees SM, Rinkel GJE, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007(3): CD000277.
  20. Upala S, Jaruvongvanich V, Wijarnpreecha K, et al. Hypomagnesemia and mortality in patients admitted to intensive care unit: a systematic review and meta-analysis. QJM. 2016; 109(7): 453–459.
  21. Johnson LH, Mapp DC, Rouse DJ, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Association of cord blood magnesium concentration and neonatal resuscitation. J Pediatr. 2012; 160(4): 573–577.e1.
  22. James MF, Cork RC, Harlen GM, et al. Interactions of adrenaline and magnesium on the cardiovascular system of the baboon. Magnesium. 1988; 7(1): 37–43.
  23. Mayer DB, Miletich DJ, Feld JM, et al. The effects of magnesium salts on the duration of epinephrine-induced ventricular tachyarrhythmias in anesthetized rats. Anesthesiology. 1989; 71(6): 923–928.
  24. Rysánek K, König J, Spánková H, et al. The effect of magnesium on the aggregation of human thrombocytes induced by adrenaline. Act Nerv Super (Praha). 1970; 12(3): 258–259.
  25. Brown CG, Griffith RF, Neely D, et al. The effect of intravenous magnesium administration on aortic, right atrial and coronary perfusion pressures during CPR in swine. Resuscitation. 1993; 26(1): 3–12.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl